We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.
- Authors
Lawler, Patrick R.; Liu, Hongyan; Frankfurter, Claudia; Lovblom, Leif Erik; Lytvyn, Yuliya; Burger, Dylan; Burns, Kevin D.; Brinc, Davor; Cherney, David Z.I.
- Abstract
In the article, the authors present their post hoc exploratory analysis to determine the changes in cardiovascular biomarkers related to sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with type 2 diabetes and chronic kidney disease (CKD). Also cited are the studies showing the effectiveness of the inhibitors in reducing risk of cardiovascular disease, and other topics like neurohormones and natriuretic peptides.
- Subjects
TYPE 2 diabetes; CHRONIC kidney failure; BRAIN natriuretic factor; EMPAGLIFLOZIN; CHRONICALLY ill
- Publication
Diabetes Care, 2021, Vol 44, Issue 3, pe45
- ISSN
0149-5992
- Publication type
letter
- DOI
10.2337/dc20-2265